• Kedra L Wallace, Venessia Johnson, Victoria Sopelak, and Randall Hines.
• Department of Obstetrics & Gynecology, University of Mississippi Medical Center, Jackson, Mississippi 39216, USA. kwallace2@umc.edu
• Fertil. Steril. 2011 Oct 1; 96 (4): 1051-6.

ObjectiveTo compare the effect of clomiphene citrate (CC) and letrozole on endometrial receptivity in women with polycystic ovary syndrome (PCOS).DesignA randomized controlled trial.SettingUniversity teaching hospital.Patient(S)Ten anovulatory women with PCOS and 5 fertile ovulatory women.Intervention(S)Patients received 2.5 mg of letrozole on cycle days 3-7 (5 patients, 1 cycle) or 50 mg of CC on cycle days 5-9 (5 patients, 1 cycle).Main Outcome Measure(S)Serum estrogen (E) and progesterone (P) endometrial protein and messenger RNA (mRNA) expression of leukemia inhibitory factor (LIF), dickkhopf homolog 1 (DKK-1), fibroblast growth factor 22 (FGF-22), and endometrial mRNA expression of LIF/GP130 receptor (LIFR).Result(S)No statistically significant differences were observed between groups compared with fertile ovulatory women when serum E and P were examined, or between body mass index (BMI), and cycle day at time of biopsy. Letrozole increased mRNA expression of LIF, DKK1, LIFR, and FGF-22, whereas CC only increased endometrial mRNA expression of LIF. Letrozole mRNA expression directly translated into increased protein expression of like genes in the endometrium. The CC protein expression of DKK-1 was significantly decreased compared with controls.Conclusion(S)Letrozole positively influences a number of markers of endometrial receptivity compared with CC.Copyright © 2011 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

31 keywords...

hide…